A Study of Doripenem in Infants Less Than 12 Weeks of Age
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 52
- Registration Number
- NCT01381848
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy
Phase 2
Completed
- Conditions
- Metastatic ER+ Her2- Breast CancerPostmenopausal
- Interventions
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 297
- Registration Number
- NCT01381874
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
Phase 3
Completed
- Conditions
- Crohn's DiseaseInflammatory Bowel DiseaseIBDColitis
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 640
- Registration Number
- NCT01369342
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Phase 3
Completed
- Conditions
- ColitisInflammatory Bowel DiseaseCrohn's DiseaseIBD
- Interventions
- Drug: Placebo SCDrug: Placebo IV
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1282
- Registration Number
- NCT01369355
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Phase 3
Completed
- Conditions
- IBDInflammatory Bowel DiseaseCrohn's DiseaseColitis
- Interventions
- First Posted Date
- 2011-06-08
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 769
- Registration Number
- NCT01369329
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Phase 1
Completed
- Conditions
- Ejaculation
- Interventions
- Drug: Treatment sequence 1Drug: Treatment sequence 2
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2014-10-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT01366664
A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1
- Registration Number
- NCT01366651
Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT01362699
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Phase 3
Completed
- Conditions
- Advanced Liposarcoma or Leiomyosarcoma
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 579
- Registration Number
- NCT01343277
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis
Phase 1
Completed
- Conditions
- Osteoarthritis, Knee
- Interventions
- First Posted Date
- 2011-04-28
- Last Posted Date
- 2012-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01343303
© Copyright 2025. All Rights Reserved by MedPath